Pulmonary Hypertension in Trisomy 18: Role of Pre-Operative Cardiac Catheterization in Select Cases

Abhishek Chakraborty1, D. Byron Holt2, Karen Wright2 and Hitesh Agrawal2*

1Le Bonheur Children’s Hospital, The University of Tennessee Health Sciences Center, USA
2Pediatric and Congenital Cardiology Associates, The University of Texas at Austin Dell Medical School, USA

Abstract
Cardiac catheterization was done in a patient with Trisomy 18 and atrio-ventricular septal defect, large inlet VSD, and poly-valvular dysplasia prior to consideration of surgical AVSD repair. The patient had severe pulmonary hypertension with severely elevated end diastolic pressures in both ventricles. Pulmonary vascular resistance was found to be 7.5 Wood units/m², with poor reactivity to oxygen and nitric oxide. Patient was thus managed conservatively without any surgical interventions.

INTRODUCTION
Trisomy 18 (T18) is associated with multiple cardiac anomalies [1,2]. Although surgical intervention is feasible, appropriate patient selection is key [3,4]. Important factors that lead to morbidity and mortality in these patients are congestive heart failure and pulmonary hypertension [5,6]. Accurate pre-operative assessment of pulmonary vascular resistance is critical in surgical planning of selected patients with clinical concerns about pulmonary hypertension.

CASE PRESENTATION
We describe a patient with a prenatal diagnosis of T18 who was born at 34.6 weeks due to maternal pre-eclampsia. The cardiac diagnosis was consistent with atrio-ventricular septal defect with a large inlet ventricular septal defect (VSD), and poly-valvular dysplasia. Additional significant co-morbidity included trachea-esophageal fistula, which needed placement of a gastrostomy tube. She also had significant lung disease related to prematurity, and over the course of time evolved into ventilator and tracheostomy dependency.

Surgical AVSD repair was planned following establishment of stable respiratory support (in the form of home ventilatory settings). However, closer to the surgical procedure, around 6-months of age, it was noted that the patient had shown progressive worsening of the right ventricular hypertrophy and bidirectional shunting across the ventricular septal defect. Additionally, her saturations were noted to be in the mid-80s on 30% FiO2. These findings were concerning for pulmonary hypertension, and thus the patient was referred for cardiac catheterization.

Baseline hemodynamics showed Qp:Qs ratio of 0.7. The mean pressure in the main pulmonary artery was severely elevated to 55 mmHg, with pulmonary capillary wedge pressure of 10 mmHg, and pulmonary vascular resistance of 7.5 Wood units/m². The right ventricular end-diastolic pressure was elevated to 15 mmHg (Table 1). After introduction of pulmonary vasodilators with 100% oxygen and 40 ppm of nitric oxide, the Qp:Qs increased to 1.5, but there was minimal change in the pulmonary vascular resistance which measured 5.6 Wood units/m² (Table 2). He also had severely elevated end diastolic pressures of 15mmHg in both ventricles at baseline. Based on significant pulmonary hypertension with poor reactivity to pulmonary vasodilators, the patient was deemed a poor surgical candidate and was

Table 1: Baseline hemodynamic and saturation data (On 21% FiO2).

<table>
<thead>
<tr>
<th>Pressure Data</th>
<th>Saturation Data</th>
</tr>
</thead>
<tbody>
<tr>
<td>Right atrium: 14/10 Mean 9 mm Hg</td>
<td>Superior venacava: 69%</td>
</tr>
<tr>
<td>Right Ventricle: 80/15 mmHg</td>
<td>Pulmonary artery: 73%</td>
</tr>
<tr>
<td>Main Pulmonary artery: 75/42 Mean 55 mmHg</td>
<td>Assumed Pv: 90% (lung disease)</td>
</tr>
<tr>
<td>Left pulmonary artery wedge: Mean 10 mmHg</td>
<td></td>
</tr>
<tr>
<td>Left Ventricle: 80/15 mmHg</td>
<td></td>
</tr>
<tr>
<td>Ulnar artery: 91/47, Mean 62 mmHg</td>
<td>Ulnar artery: 81%</td>
</tr>
<tr>
<td>Qp/Qs: 0.7:1</td>
<td>PVRi = 7.5 WU/m²</td>
</tr>
</tbody>
</table>
discharged home with medical management for pulmonary hypertension. The patient currently is 14-month-old living with severe pulmonary hypertension, and being managed medically with Sildenafil. The family declined initiation of Bosentan. In the interim, there have been several hospital admissions due to pulmonary hypertensive crises, mostly in the setting of acute infections.

DISCUSSION

Trisomy 18 is associated with multiple congenital cardiac heart defects including atrial septal defects, ventricular septal defects, atrio-ventricular septal defects, patent ductus arteriosus, and valvular dysplasia [2, 6-8]. Historically, the natural course of illness in most of these patients is death in the first year of life, most commonly related to central apnea and aspiration, potentially unrelated to heart defects [7,8]. Over the past two decades, with advances in surgical techniques and evolution of multi-disciplinary management, an increasing number of these infants are undergoing a variety of interventions, including cardiac surgery [7-12]. A recent review of the Society of Thoracic Surgeons Congenital Heart Surgery database (STS-CHSD), showed that 70% of STS centers performed surgery on T18 patients. In a span of 8 years (between 2010 to 2017), 270 cardiac surgeries were done in T18 patients, with a significant number being high risk patients (26.7% in STAT 4 and STAT 5 categories) [11]. Incidence of perioperative complications remain high (55%) in T18 patients with a significant in-hospital mortality up to 15.6% [9]. Additionally, the overall five-year survival for patients with Trisomy 18 remains grim (12.3%) [9]. Hence, careful planning and risk assessment, prior to undergoing cardiac surgical interventions is very important.

Pulmonary hypertension is common in T18 patients, and is an important contributor to morbidity [5,6,12]. In a retrospective multicenter study from Japan published recently, pulmonary hypertension was present in up to 42% of T18 patients [11]. Similarly, a retrospective review of the Pediatric Cardiac Care Consortium (PCCC) identified pulmonary hypertension in 10.8% of T18 patients undergoing cardiac surgery [10]. A single center retrospective study published recently identified that in patients with complete repair, a large majority (75%) had evidence of pulmonary hypertension post-operatively. At discharge, nearly half of the patients (45%) required supplemental oxygen, and 27% were placed on an additional pulmonary vasodilator, such as sildenafil or bosentan [12]. Thus, it is evident that pulmonary hypertension is prevalent in a substantial number of T18 patients, both pre-operatively, as well as after surgery. This contributes to the post-operative morbidity/mortality, requiring additional therapies and hospital length of stay.

Echocardiogram is a good non-invasive imaging modality for serial evaluation of these patients. However, direct measurement of pulmonary artery and right ventricular pressures is considered gold standard for assessment of pulmonary hypertension. In addition, the contribution of shunts, and the response to pulmonary vasodilators can be assessed as well, to guide surgical planning. Patients with pulmonary over-circulation (Qp:Qs >1.5) and reactive pulmonary vascular bed will benefit from closure of the shunts. However, surgical intervention is contraindicated in patients with severe pulmonary hypertension, a non-reactive pulmonary vascular bed and Qp:Qs <1.

Pre-operative ventilator dependency, prematurity, earlier age and weight at procedure, pulmonary hypertension and ductal dependent cardiac lesions portend worse prognosis for these patients. Hence, clinical decision making requires a multi-disciplinary team approach between primary care, neonatologists, cardiologists, surgeons and the family. Ongoing longitudinal research is required in these patients to establish standard of care and to improve quality of life of these individuals (Video 1,2).

In summary, pulmonary hypertension is common in T18 patients with congenital heart disease. This has a significant bearing on surgical planning for those individuals suspected to
have pulmonary hypertension. Cardiac catheterization prior to surgery is extremely useful in select cases to determine the degree of pulmonary hypertension, and vaso-reactivity to pulmonary vasodilators. Those with non-reactive pulmonary hypertension should be managed medically.

REFERENCES


